{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"39","upperLimit":"61","value":"50"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"}],"units":"Participants"}],"description":"Complete clinical and pathologic response is defined as the disappearance of all gross tumor during chemoradiation with no residual tumor present in the surgical specimen.","dispersionType":"90% Confidence Interval","groups":[{"description":"Radiation therapy to the vulva, inguinal-femoral, and lower pelvic lymph nodes by AP-PA fields (180 cGy/daily fraction X 5 days, repeated weekly to a total of 32 fractions- total dose 5760 Gy). Concurrent cisplatin (40 mg/m2) chemotherapy administered weekly throughout radiation therapy. Six to eight weeks following the completion of chemoradiation - surgical excision of gross residual disease in the vulva and/or inguinal-femoral lymph nodes (if the inguinal-femoral nodes were considered unresectable prior to chemoradiation).","id":"OG000","title":"Cisplatin + Radiation, Then Surgery"}],"paramType":"NUMBER","populationDescription":"Eligible and treated patients","reportingStatus":"POSTED","timeFrame":"Seven weeks after initiating treatment for clinical response and up to fifteen weeks for assessment of pathologic response.","title":"Complete Clinical and Pathologic Response","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}